Download PDF
J Pediatr Intensive Care 2021; 10(02): 152-154
DOI: 10.1055/s-0040-1710496
Case Report

Dantrolene-Induced Hepatitis: A Rare Culprit in the PICU

Divij Pasrija 
1   Department of Pediatric Critical Care, Oishei Children's Hospital, University of Buffalo, Buffalo, New York, United States
,
Shilpi Gupta
2   Department of Internal Medicine, Mercy Hospital of Buffalo, Buffalo, New York, United States
,
Amanda Hassinger
1   Department of Pediatric Critical Care, Oishei Children's Hospital, University of Buffalo, Buffalo, New York, United States
› Author Affiliations Funding None.
› Further Information
    Permissions and Reprints

Abstract

Dantrolene is used for reversal of malignant hyperthermia and for improvement in spasticity following stroke which are Food and Drug Administration-approved indications. It is an infrequently used medication in the pediatric intensive care unit and is usually continued from the operating room or sedation suite after suspicion for malignant hyperthermia, secondary to other medications and anesthetic agents. Hepatitis has been described as a side effect of the medication after prolonged use and at doses of more than 100 mg/d mainly in adults. We described in this case report a patient in which the drug was used for sympathetic overactivity in the PICU and development of asymptomatic hepatitis on day 3 after starting the medication at a dose much lower than previously described.

Keywords

dantrolene - spasticity - hepatitis - toxicity

Authors' Contributions

D. P. was primarily involved in preparation of manuscript. S. G. and A. H. provided assistance with literature review and manuscript submission.




Publication History

Received: 30 September 2019

Accepted: 06 April 2020

Article published online:
05 June 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 USFDA- Drug database; DANTROLENE SODIUM; Label - supplement 49. Accessed November, 2019 at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205579s000lbl.pdf
  • 2 Ward A, Chaffman MO, Sorkin EM. Dantrolene. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in malignant hyperthermia, the neuroleptic malignant syndrome and an update of its use in muscle spasticity. Drugs 1986; 32 (02) 130-168
    CrossrefPubMedGoogle Scholar
  • 3 Denhoff E, Feldman S, Smith MG, Litchman H, Holden W. Treatment of spastic cerebral-palsied children with sodium dantrolene. Dev Med Child Neurol 1975; 17 (06) 736-742
    CrossrefPubMedGoogle Scholar
  • 4 Utili R, Boitnott JK, Zimmerman HJ. Dantrolene-associated hepatic injury. Incidence and character. Gastroenterology 1977; 72 (4 Pt 1): 610-616
    CrossrefPubMedGoogle Scholar
  • 5 Chan CH. Dantrolene sodium and hepatic injury. Neurology 1990; 40 (09) 1427-1432
    CrossrefPubMedGoogle Scholar
  • 6 Kim JY, Chun S, Bang MS, Shin HI, Lee SU. Safety of low-dose oral dantrolene sodium on hepatic function. Arch Phys Med Rehabil 2011; 92 (09) 1359-1363
    CrossrefPubMedGoogle Scholar
  • 7 Wilkinson SP, Portmann B, Williams R. Hepatitis from dantrolene sodium. Gut 1979; 20 (01) 33-36
    CrossrefPubMedGoogle Scholar
  • 8 Guengerich FP, MacDonald JS. Applying mechanisms of chemical toxicity to predict drug safety. Chem Res Toxicol 2007; 20 (03) 344-369
    CrossrefPubMedGoogle Scholar